These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18635232)

  • 1. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
    Bhave G; Lewis JB; Chang SS
    J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis: a report of 29 cases.
    Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
    AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.
    Collidge TA; Thomson PC; Mark PB; Traynor JP; Jardine AG; Morris ST; Simpson K; Roditi GH
    Radiology; 2007 Oct; 245(1):168-75. PubMed ID: 17704357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
    Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
    Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy.
    Stratta P; Canavese C; Aime S
    Curr Med Chem; 2008; 15(12):1229-35. PubMed ID: 18473815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
    Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
    J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: a chemical perspective.
    Rofsky NM; Sherry AD; Lenkinski RE
    Radiology; 2008 Jun; 247(3):608-12. PubMed ID: 18487530
    [No Abstract]   [Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis: is gadolinium the missing piece to the puzzle?
    Bennett LK; Garrett AL
    Cutis; 2008 May; 81(5):421-6. PubMed ID: 18543594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.
    Reilly RF
    Clin J Am Soc Nephrol; 2008 May; 3(3):747-51. PubMed ID: 18287249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis and gadolinium: a perfect storm.
    Colletti PM
    AJR Am J Roentgenol; 2008 Oct; 191(4):1150-3. PubMed ID: 18806157
    [No Abstract]   [Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis: a concise review for cardiologists.
    Cheong BY; Muthupillai R
    Tex Heart Inst J; 2010; 37(5):508-15. PubMed ID: 20978560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB; Maize JC; Woolson RF; Budisavljevic MN
    Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nephrogenic systemic fibrosis--a new interdisciplinary challenge].
    Witzke O; Hillen U; Barkhausen J; Daul A; Kribben A
    Dtsch Med Wochenschr; 2007 Dec; 132(50):2706-10. PubMed ID: 18058663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH; Murphy KJ
    J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.
    Ersoy H; Rybicki FJ
    J Magn Reson Imaging; 2007 Nov; 26(5):1190-7. PubMed ID: 17969161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.